Themis Medicare Limited has announced the pledge of 9,20,000 equity shares of Gujarat Themis Biosyn Limited on December 30, 2025, as part of a strategic financial restructuring initiative. The disclosure was made under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, highlighting the company's commitment to regulatory compliance and transparency.

Pledge Details and Financial Structure

The pledge arrangement involves a comprehensive facility cum pledge agreement with Jio Credit Limited for a borrowing amount of ₹10.00 crores. The transaction represents a calculated financial move designed to optimize the company's debt portfolio and reduce overall financing costs.

Shareholding Impact and Ownership Structure

The pledge significantly impacts Themis Medicare's shareholding position in Gujarat Themis Biosyn Limited. Prior to this transaction, Themis Medicare held 2,52,72,037 shares, representing 23.19% of the total share capital of Gujarat Themis Biosyn.

Strategic Financial Restructuring

The pledge arrangement forms part of Themis Medicare's broader financial optimization strategy. The company has specifically stated that the ₹10.00 crore facility will be utilized for repaying existing high-interest-bearing loans, thereby reducing the overall finance cost burden. This approach demonstrates prudent financial management and cost optimization initiatives.

Regulatory Compliance and Disclosure

The disclosure was filed with both the National Stock Exchange of India Limited and BSE Limited on January 2, 2026, ensuring full compliance with regulatory requirements. The transaction was executed under a formal facility cum pledge agreement, providing structured terms and conditions for both parties involved in the arrangement.

The pledge represents a strategic financial decision that balances the need for cost-effective borrowing while maintaining regulatory compliance and transparency standards required for listed entities.

Gujarat Themis Biosyn Limited (GTBL) has reported a significant increase in its financial performance for the second quarter, alongside a major expansion in its manufacturing capabilities.

Financial Highlights

The company's Q2 financial results show robust growth in profitability:

GTBL's performance demonstrates strong improvement in both top-line growth and profitability.

Operational Expansion

In a significant development, GTBL has completed the expansion of its Fermentation Block at its manufacturing facilities in Vapi, Gujarat. Key points of this expansion include:

• Commercial production of Rifamycin-S and Rifamycin-O commenced on October 18, 2025.
• The overall fermentation capacity has increased from 450 KL to 990 KL, more than doubling the previous capacity.
• This expansion strengthens GTBL's capabilities to produce multiple fermentation products.

Board Appointment

GTBL has appointed Mr. Rajneesh Anand as Additional Non-Executive Non-Independent Director for a five-year term effective November 10, 2025. Mr. Anand brings valuable experience to the board:

• He is a mechanical engineering graduate with management qualifications.
• Has been associated with Themis Group since 1977.
• Currently serves as Director of Themis Medicare Limited.

Outlook

With the expanded fermentation capacity and improved financial performance, Gujarat Themis Biosyn appears well-positioned in the bulk drugs manufacturing sector. The company's focus on enhancing its production capabilities aligns with the demand for pharmaceutical ingredients.